Wholly-owned subsidiary of Guardian Therapeutics.
Inventor and development sponsor of BT200, a VWF binding aptamer in clinical development for treatment of hereditary bleeding disorders.
Specialized in application of aptamer therapeutic technology to diseases related to Von Willebrand Factor.
Zhu et al, J Thromb Haemost. 2020 Feb 3.
BT200 is a PEGylated aptamer that binds A1 domain of human VWF.
BT200 Phase 1 program (NCT04103034) was completed in 4Q20.
BT200 Phase 2 pilot study in hereditary bleeding disorders (NCT04677803) initiated in 1Q21.